|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. PharmaMar |
|---|---|
| Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT00050440 |
Purpose
This is a study is to test the safety and effectiveness of an investigational chemotherapy agent in subjects with persistent or recurrent endometrial cancer. After a subject meets all entry criteria and signs informed consent she will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.
| Condition | Intervention | Phase |
|---|---|---|
|
Endometrial Neoplasms |
Drug: ET-743 |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Contacts and Locations| United States, California | |
| USC, Norris Comprehensive Cancer Center | |
| Los Angeles, California, United States, 90089 | |
| United States, Connecticut | |
| Hematology Oncology P.C. | |
| Stamford, Connecticut, United States, 06902 | |
| United States, Florida | |
| University of Miami, Sylvester Comprehensive Cancer Center | |
| Miami, Florida, United States, 33136 | |
| United States, Kentucky | |
| Northon Hospitals, Inc., Louisville Oncology | |
| Louisville, Kentucky, United States, 40202 | |
| University of Kentucky, Chandler Medical Center | |
| Lexington, Kentucky, United States, 40536 | |
| United States, Louisiana | |
| Hematology Oncology Specialists | |
| New Orleans, Louisiana, United States, 70115 | |
| Ochsner Cancer Institute | |
| New Orleans, Louisiana, United States, 70121 | |
| United States, Maryland | |
| Franklin Square Hospital Center | |
| Baltimore, Maryland, United States, 21237 | |
| United States, New Jersey | |
| University of Medicine & Dentistry of NJ | |
| Newark, New Jersey, United States | |
| United States, New York | |
| NYU School of Medicine | |
| New York, New York, United States, 10016 | |
| United States, Ohio | |
| Cleveland Clinic Foundation, Taussig Cancer Center | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Oklahoma | |
| University of Oklahoma Health Science Center | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, South Carolina | |
| MUSC, Hollings Cancer Center | |
| Charleston, South Carolina, United States, 29425 | |
| United States, Tennessee | |
| Vanderbilt-Ingram Cancer Center | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Texas | |
| US Oncology, Dallas | |
| Dallas, Texas, United States, 75204 | |
More Information
| Study ID Numbers: | ET743-USA-1 |
| Study First Received: | December 9, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00050440 |
| Health Authority: | United States: Food and Drug Administration |
|
endometrial cancer endometrial cancer endometrial carcinoma |
|
Ecteinascidin 743 Genital Diseases, Female Endometrial Neoplasms Genital Neoplasms, Female Uterine Diseases |
Uterine Neoplasms Urogenital Neoplasms Endometrial cancer Recurrence Carcinoma |
|
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Antineoplastic Agents, Alkylating Alkylating Agents Pharmacologic Actions |
